Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Nat Commun
2019 Jan 18;101:321. doi: 10.1038/s41467-019-08291-1.
Show Gene links
Show Anatomy links
Structural elements of a pH-sensitive inhibitor binding site in NMDA receptors.
Regan MC
,
Zhu Z
,
Yuan H
,
Myers SJ
,
Menaldino DS
,
Tahirovic YA
,
Liotta DC
,
Traynelis SF
,
Furukawa H
.
???displayArticle.abstract???
Context-dependent inhibition of N-methyl-D-aspartate (NMDA) receptors has important therapeutic implications for the treatment of neurological diseases that are associated with altered neuronal firing and signaling. This is especially true in stroke, where the proton concentration in the afflicted area can increase by an order of magnitude. A class of allosteric inhibitors, the 93-series, shows greater potency against GluN1-GluN2B NMDA receptors in such low pH environments, allowing targeted therapy only within the ischemic region. Here we map the 93-series compound binding site in the GluN1-GluN2B NMDA receptor amino terminal domain and show that the interaction of the N-alkyl group with a hydrophobic cage of the binding site is critical for pH-dependent inhibition. Mutation of residues in the hydrophobic cage alters pH-dependent potency, and remarkably, can convert inhibitors into potentiators. Our study provides a foundation for the development of highly specific neuroprotective compounds for the treatment of neurological diseases.
Fig. 1. pH-sensitive negative allosteric modulators of GluN2B-containing NMDA receptors. a The 93-series compounds28 are shown together with the phenylethanolamine ifenprodil and EVT-101. b Representative TEVC recordings of wild-type GluN1-4a/GluN2B NMDA receptors in Xenopus oocytes are shown in response to maximally effective concentration of glutamate and glycine (100 and 30 μM, respectively). When normalized to the maximal response, recordings at pH 6.9 showed substantially higher potency of 93-31 than at pH 7.6. c Concentration–response curves from TEVC experiments at pH 7.6 (gray) and 6.9 (black) for inhibition of wild-type GluN1-4a/GluN2B NMDA receptor by 93-31 (also see Table 2). Symbols and error bars represent mean ± S.E.M.; the number of replicates is listed in Table 2
Fig. 2. ITC titrations of the GluN1/GluN2B ATD with different ligands at pH 7.6 and 6.5. Representative ITC isotherms of the isolated GluN1-GluN2B ATD titrated with 93-31 at pH 7.6 (a) and 6.5 (b). The average dissociation constant (KD) for 93-31 at pH 7.6 was 121 ± 5.1 nM, which drops to 78.4 ± 2.97 nM at pH 6.5 (Table 1). c Dissociation constants for various 93-series ligands at pH 7.6 (black bar) and pH 6.5 (gray bar). d The ratio of the KD at pH 7.6 to the KD at 6.5 (pH-boost) is shown as a function of N-substituent volume. For all panels, error bars represent mean ± S.E.M. All experiments were performed in triplicate
Fig. 3. Structure of the 93-series binding site. a The intact heterotetrameric GluN1b/GluN2B NMDA receptor34 is composed of three structured domains, with the ATD furthest from the cell membrane (PDB code: 6CNA). b, c The crystal structure of the isolated GluN1b/GluN2B ATD heterodimer bound to the pH-sensitive 93-31 reveals the ligand-binding site at the heterodimer interface, as viewed from two angles. d, e The key residues surrounding the N-alkyl chain of 93-31 are primarily hydrophobic, shown here in stereo view. f Overlay of 93-31 and ifenprodil25 (yellow, PDB code: 3QEL). g Overlay of 93-31 and EVT-101 (ref. 29) (green, PDB code: 5EWM)
Fig. 4. TEVC concentration–response curves for GluN1-4a–GluN2B mutants. a The N-alkyl group of 93-31 is accommodated by the “hydrophobic cage” as shown by the hydrophobic (red) to non-hydrophobic (white) surface presentation. b Key residues at the GluN1/GluN2B ATD dimer interface that interact with the N-alkyl chain of 93-31 were mutated and evaluated for effects on pH sensitivity of 93-31. c–i Current responses to maximally effective concentration of glutamate and glycine (100 μM glutamate, 30 μM glycine) are shown in the presence of varying concentrations of 93-31 as a proportion of maximal response. Experiments conducted at pH 7.6 are shown in gray; experiments at pH 6.9 are shown in black. h, j Two mutations, GluN1-4a(His134Ala) and GluN1-4a(Tyr109Trp), convert 93-31 into a potentiator. Experiments here were performed at pH 7.6 (gray), with the wild-type curve displayed for comparison (black). Error bars represent mean ± S.E.M. See Tables 2 and 3 for fitted IC50 values and the number of independent replicates
Braun,
Dynamic brain network reconfiguration as a potential schizophrenia genetic risk mechanism modulated by NMDA receptor function.
2016, Pubmed
Braun,
Dynamic brain network reconfiguration as a potential schizophrenia genetic risk mechanism modulated by NMDA receptor function.
2016,
Pubmed
Chen,
Functional Evaluation of a De Novo GRIN2A Mutation Identified in a Patient with Profound Global Developmental Delay and Refractory Epilepsy.
2017,
Pubmed
Choi,
The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death.
1990,
Pubmed
Coyle,
Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia.
2010,
Pubmed
Coyle,
NMDA receptor and schizophrenia: a brief history.
2012,
Pubmed
Esmenjaud,
An inter-dimer allosteric switch controls NMDA receptor activity.
2019,
Pubmed
,
Xenbase
Furukawa,
Structure and function of glutamate receptor amino terminal domains.
2012,
Pubmed
Hansen,
Structural determinants of agonist efficacy at the glutamate binding site of N-methyl-D-aspartate receptors.
2013,
Pubmed
,
Xenbase
Hansen,
Structure, function, and allosteric modulation of NMDA receptors.
2018,
Pubmed
Jespersen,
Structural insights into competitive antagonism in NMDA receptors.
2014,
Pubmed
,
Xenbase
Karakas,
Subunit arrangement and phenylethanolamine binding in GluN1/GluN2B NMDA receptors.
2011,
Pubmed
,
Xenbase
Karakas,
Crystal structure of a heterotetrameric NMDA receptor ion channel.
2014,
Pubmed
Katsura,
Coupling among changes in energy metabolism, acid-base homeostasis, and ion fluxes in ischemia.
1992,
Pubmed
Lee,
NMDA receptor structures reveal subunit arrangement and pore architecture.
2014,
Pubmed
,
Xenbase
Lemke,
Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes.
2013,
Pubmed
,
Xenbase
Liu,
NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo.
2007,
Pubmed
Lü,
Cryo-EM structures of the triheteromeric NMDA receptor and its allosteric modulation.
2017,
Pubmed
,
Xenbase
Martel,
The subtype of GluN2 C-terminal domain determines the response to excitotoxic insults.
2012,
Pubmed
Nedergaard,
Dynamics of interstitial and intracellular pH in evolving brain infarct.
1991,
Pubmed
Paoletti,
NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease.
2013,
Pubmed
Parsons,
Extrasynaptic NMDA receptor involvement in central nervous system disorders.
2014,
Pubmed
Preskorn,
An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.
2008,
Pubmed
Regan,
Structural Mechanism of Functional Modulation by Gene Splicing in NMDA Receptors.
2018,
Pubmed
,
Xenbase
Regan,
A structural biology perspective on NMDA receptor pharmacology and function.
2015,
Pubmed
Romero-Hernandez,
Novel Mode of Antagonist Binding in NMDA Receptors Revealed by the Crystal Structure of the GluN1-GluN2A Ligand-Binding Domain Complexed to NVP-AAM077.
2017,
Pubmed
,
Xenbase
Romero-Hernandez,
Molecular Basis for Subtype Specificity and High-Affinity Zinc Inhibition in the GluN1-GluN2A NMDA Receptor Amino-Terminal Domain.
2016,
Pubmed
,
Xenbase
Rothman,
Excitotoxicity and the NMDA receptor--still lethal after eight years.
1995,
Pubmed
Ruiz,
A potentially simpler approach to measure aqueous pKa of insoluble basic drugs containing amino groups.
2003,
Pubmed
Stroebel,
A Novel Binding Mode Reveals Two Distinct Classes of NMDA Receptor GluN2B-selective Antagonists.
2016,
Pubmed
,
Xenbase
Tahirovic,
Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists.
2008,
Pubmed
,
Xenbase
Tajima,
Activation of NMDA receptors and the mechanism of inhibition by ifenprodil.
2016,
Pubmed
Traynelis,
Glutamate receptor ion channels: structure, regulation, and function.
2010,
Pubmed
Vance,
Ligand-specific deactivation time course of GluN1/GluN2D NMDA receptors.
2011,
Pubmed
Wang,
pH-sensitive NMDA inhibitors improve outcome in a murine model of SAH.
2014,
Pubmed
Yuan,
Context-dependent GluN2B-selective inhibitors of NMDA receptor function are neuroprotective with minimal side effects.
2015,
Pubmed